What to expect in 2024: important health economics and outcomes research (HEOR) trends

References

• Shafrin J, Lakdawalla DN, Doshi JA, et al. A strategy for value-based drug pricing under the inflation reduction act. Health Affairs. [cited 2023 Dec 11]. Available from: https://www.healthaffairs.org/content/forefront/strategy-value-based-drug-pricing-under-inflation-reduction-act.
   Google Scholar
• Institute for Clinical and Economic Review (ICER). [cited 2023 Dec 11]. Available from: https://icer.org/our-approach/methods-process/cost-effectiveness-the-qaly-and-the-evlyg/.
   Google Scholar
• Lakdawalla DN, Phelps CE. Health technology assessment with diminishing returns to health: the generalized risk-adjusted cost-effectiveness (GRACE) approach. Value Health. 2020;24(2):244–249. doi: 10.1016/j.jval.2020.10.003.
   Web of Science ®Google Scholar
• Lakdawalla DN, Phelps CE. The generalized risk-adjusted cost-effectiveness (GRACE) model for measuring the value of gains in health: an exact formulation. Journal of Benefit-Cost Analysis. 2023;14(1):44–67. doi: 10.1017/bca.2023.6.
   Google Scholar
• Marsh K, van Til JA, Molsen-David E, et al. Health preference research in Europe: a review of its use in marketing authorization, reimbursement, and pricing decisions-report of the ISPOR stated preference research special interest group. Value Health. 2020;23(7):831–841. doi: 10.1016/j.jval.2019.11.009.
   PubMed Web of Science ®Google Scholar
• Bouvy JC, Cowie L, Lovett R, et al. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145–149. doi: 10.1007/s40271-019-00408-4.
   PubMedGoogle Scholar
• Shiozawa A, Thurston RC, Cook E, et al. Assessment of women’s treatment preferences for vasomotor symptoms due to menopause. Expert Rev Pharmacoecon Outcomes Res. 2023;23(10):1117–1128. doi: 10.1080/14737167.2023.2250916.
   PubMed Web of Science ®Google Scholar
• Böger S, van Bergen I, Beaudart C, et al. Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2023;23(8):921–931. doi: 10.1080/14737167.2023.2223983.
   PubMed Web of Science ®Google Scholar
• Willems D, Sayed CJ, Van der Zee HH, et al. A discrete-choice experiment to elicit the treatment preferences of patients with hidradenitis suppurativa in the United States. J Med Econ. 2023;26(1):503–508. doi: 10.1080/13696998.2023.2194804.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. [cited 2023 Dec 11]. Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence.
   Google Scholar
• US Food & Drug Administration. [cited 2023 Dec 11]. Available from: https://www.fda.gov/science-research/focus-areas-regulatory-science-report/focus-area-artificial-intelligence.
   Google Scholar
• Arlett P, Kjaer J, Broich K, et al. Real‐world evidence in EU medicines regulation: enabling use and establishing value. Clin otPharmacol Ther. 2022;111(1):21–23. doi: 10.1002/cpt.2479.
   PubMed Web of Science ®Google Scholar
• Sarri G. Can real-world evidence help restore decades of health inequalities by informing health care decision-making? Certainly, and here is how. Front Pharmacol. 2022;13:905820. doi: 10.3389/fpharm.2022.905820.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. [cited 2023 Dec 11]. Available from: https://www.who.int/health-topics/health-equity#tab=tab_1.
   Google Scholar
• Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344–2350. doi: 10.1001/jama.291.19.2344.
   PubMed Web of Science ®Google Scholar
• Huskamp HA, Deverka PA, Epstein AM, et al. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224–2232. doi: 10.1056/NEJMsa030954.
   PubMed Web of Science ®Google Scholar
• Franklin JM, Lin KJ, Gatto NM, et al. Real-World evidence for assessing pharmaceutical treatments in the context of COVID-19. Clin Pharma Therapeut. 2021;109(4):816–828. doi: 10.1002/cpt.2185.
   PubMed Web of Science ®Google Scholar
• Love-Koh J, Cookson R, Gutacker N, et al. Aggregate distributional cost-effectiveness analysis of health technologies. Value Health. 2019;22(5):518–526. doi: 10.1016/j.jval.2019.03.006.
   PubMed Web of Science ®Google Scholar
• Roldós MI, Breen N. Using economic evaluation to hasten equity. Health Equity. 2021;5(1):627–632. doi: 10.1089/heq.2021.0010.
   PubMedGoogle Scholar
• World Health Organisations. WHO model list of essential medicines – 23rd list; 2023 [cited 2023 Oct 12]. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02.
   Google Scholar
• WHO. Model list of essential medicines for children – 9th list; 2023 [cited 2023 Oct 12]. Available from: https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.03.
   Google Scholar
• Daems R. Medicines for the developing world: innovation and economic policy. Maastricht, The Netherlands: Universitaire Pers Maastricht; 2008.
   Google Scholar
• Abraham I. 1 Billion people can access biosimilars; what about the other 7 billion? Center for Biosimilars; 2023 [cited 2023 Oct 12]. Available from: https://www.centerforbiosimilars.com/view/dr-ivo-abraham-column-1-billion-people-can-access-biosimilars-wh at-about-the-other-7-billion-.
   Google Scholar
• Halawah HH, Alkhatib NS, Almutairi AR, et al. Cost-efficiency analysis and expanded treatment access modeling of conversion to rituximab biosimilars from reference rituximab in Jordan. J Med Econ. 2023;26(1):835–842. doi: 10.1080/13696998.2023.2226007.
   PubMed Web of Science ®Google Scholar
• Oh M, McBride A, Bhattacharjee S, et al. The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Rev Pharmacoecon Outcomes Res. 2023;23(3):309–316. doi: 10.1080/14737167.2023.2169135.
   PubMed Web of Science ®Google Scholar
• Diakite I, Nguyen S, Sabale U, et al. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases. J Med Econ. 2023;26(1):1085–1098. doi: 10.1080/13696998.2023.2250194.
   PubMed Web of Science ®Google Scholar
• Al-Omar HA, Aljehani N, Alshehri A, et al. Ten-year cost-consequence analysis of weight loss on obesity-related outcomes in privately insured adults with obesity in Saudi Arabia. J Med Econ. 2023;26(1):802–810. doi: 10.1080/13696998.2023.2221570.
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Chapman RH, Pearson SD. Evaluating and valuing drugs for rare conditions: no easy answers. Value Health. 2018;21(5):547–552. doi: 10.1016/j.jval.2018.01.008.
   PubMed Web of Science ®Google Scholar
• Adkins EM, Nicholson L, Floyd D, et al. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? Clinicoecon Outcomes Res. 2017;9:327–342. doi: 10.2147/CEOR.S134230.
   PubMed Web of Science ®Google Scholar
• CDER. Continues to advance rare disease drug development with new efforts, FDA.gov; 2023 [cited Nov 6]. Available from: https://www.fda.gov/drugs/news-events-human-drugs/cder-continues-advance-rare-disease-drug-development-new-efforts-including-accelerating-rare-disease.
   Google Scholar
• Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98(11):829–836. doi: 10.1093/qjmed/hci128.
   PubMed Web of Science ®Google Scholar
• Richter T, Nestler-Parr S, Babela R, et al. Rare disease terminology and definitions-a systematic global review: report of the ISPOR rare disease special interest group. Value Health. 2015;18(6):906–914. doi: 10.1016/j.jval.2015.05.008.
   PubMed Web of Science ®Google Scholar
• Takami A, Kato M, Deguchi H, et al. Value elements and methods of value-based pricing for drugs in Japan: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2023;23(7):749–759. doi: 10.1080/14737167.2023.2223984.
   PubMed Web of Science ®Google Scholar
• Makin C, Neumann P, Peschin S, et al. Modelling the value of innovative treatments for Alzheimer’s disease in the United States. J Med Econ. 2021;24(1):764–769. doi: 10.1080/13696998.2021.1927747.
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, Abraham I. The six delta platform for outcome-based contracting for pharmaceuticals. J Med Econ. 2020;23(11):1209–1214. doi: 10.1080/13696998.2020.1824161.
   PubMed Web of Science ®Google Scholar
• Alkhatib NS, McBride A, Slack M, et al. Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 δs). J Med Econ. 2020;23(11):1266–1272. doi: 10.1080/13696998.2020.1815031.
   PubMed Web of Science ®Google Scholar
• [cited 2023 Oct 13]. Available from: https://icer.org/last.
   Google Scholar
• DeTora LM, Toroser D, Sykes A, et al. Good publication practice (GPP) guidelines for Company-Sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298–1304. doi: 10.7326/M22-1460.
   PubMed Web of Science ®Google Scholar
• EudraCT. [cited 2023 Dec 11]. Available from: https://eudract.ema.europa.eu/.
   Google Scholar
• Centers for Disease Control and Prevention. [cited 2023 Dec 11]. Available from: https://wwwn.cdc.gov/nchs/nhanes/default.aspx.
   Google Scholar
• AWS Data Exchange. [cited 2023 Dec 11]. Available from: https://registry.opendata.aws/mimiciii/.
   Google Scholar
• Citrome L. Meta-analyses: editor’s dream or nightmare? Int J Clin Pract. 2013;67(11):1069–1070. doi: 10.1111/ijcp.12324.
   PubMed Web of Science ®Google Scholar